Could a diabetes pill slow lung cancer? new trial aims to find out
NCT ID NCT07272057
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether adding an SGLT2 inhibitor (a type of diabetes pill) to standard cancer treatment can help people with advanced lung cancer and diabetes live longer or slow their tumor growth. About 200 adults will take either the SGLT2 inhibitor or other diabetes drugs alongside their cancer therapy. Researchers will track survival, heart problems, and side effects to see if the drug offers extra benefits.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Personality type may influence diabetic wound healing – a study investigates
- Can a strong support network help people with diabetic kidney disease take better care of themselves?
- Eye scan may spot hidden blood-flow changes that signal glaucoma risk in diabetes
- Tight glucose control may preserve insulin-making cells in type 2 diabetes
- Breathing tube-free lung surgery tested for patients with fragile lungs
- Can standard cancer treatment wake up the immune system? a study investigates.